Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202.

Henry NL, Unger JM, Till C, Schott AF, Crew KD, Lew DL, Fisch MJ, Moinpour CM, Wade JL 3rd, Hershman DL.

Cancer. 2019 Jun 15;125(12):2123-2129. doi: 10.1002/cncr.32024. Epub 2019 Mar 12.

PMID:
30861098
2.

Factors influencing the use of extended adjuvant endocrine therapy.

Kadakia KC, Kidwell KM, Barton DL, Schott AF, Hayes DF, Griggs JJ, Henry NL.

Breast Cancer Res Treat. 2019 May;175(1):181-189. doi: 10.1007/s10549-019-05145-8. Epub 2019 Jan 31.

PMID:
30706190
3.

Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure.

Marcath LA, Kidwell KM, Robinson AC, Vangipuram K, Burness ML, Griggs JJ, Poznak CV, Schott AF, Hayes DF, Henry NL, Hertz DL.

Pharmacogenomics. 2019 Jan;20(2):95-104. doi: 10.2217/pgs-2018-0162. Epub 2018 Dec 6.

PMID:
30520341
4.

Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.

Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL.

Clin Cancer Res. 2018 Aug 1;24(15):3602-3610. doi: 10.1158/1078-0432.CCR-18-0656. Epub 2018 Apr 27.

PMID:
29703818
5.

Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.

Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng FY, Speers C, Overmoyer B, Sabel M, Schott AF, Pierce L; Translational Breast Cancer Research Consortium.

J Clin Oncol. 2018 May 1;36(13):1317-1322. doi: 10.1200/JCO.2017.77.2665. Epub 2018 Mar 20.

PMID:
29558281
6.

Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.

Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu CJ, Chu D, Yazdani M, Blevins AR, Sero V, Tokudome N, Thomas DG, Gersch C, Schott AF, Wu YM, Lonigro R, Robinson DR, Chinnaiyan AM, Bischoff FZ, Johnson MD, Park BH, Hayes DF, Rae JM, Tomlins SA.

Cancer Res. 2018 Feb 15;78(4):1110-1122. doi: 10.1158/0008-5472.CAN-17-2686. Epub 2017 Dec 12.

7.

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd.

J Clin Oncol. 2018 Feb 1;36(4):326-332. doi: 10.1200/JCO.2017.74.6651. Epub 2017 Nov 14.

8.

Integrative clinical genomics of metastatic cancer.

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, Cieślik M, Chinnaiyan AM.

Nature. 2017 Aug 17;548(7667):297-303. doi: 10.1038/nature23306. Epub 2017 Aug 2.

9.

Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.

Schott AF, Goldstein LJ, Cristofanilli M, Ruffini PA, McCanna S, Reuben JM, Perez RP, Kato G, Wicha M.

Clin Cancer Res. 2017 Sep 15;23(18):5358-5365. doi: 10.1158/1078-0432.CCR-16-2748. Epub 2017 May 24.

10.

Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps.

Park J, Wysocki RW, Amoozgar Z, Maiorino L, Fein MR, Jorns J, Schott AF, Kinugasa-Katayama Y, Lee Y, Won NH, Nakasone ES, Hearn SA, Küttner V, Qiu J, Almeida AS, Perurena N, Kessenbrock K, Goldberg MS, Egeblad M.

Sci Transl Med. 2016 Oct 19;8(361):361ra138.

11.

Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622.

Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN.

Breast Cancer Res Treat. 2016 Aug;159(1):87-95. doi: 10.1007/s10549-016-3911-z. Epub 2016 Jul 30.

12.

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN.

Breast Cancer Res Treat. 2016 Aug;158(3):485-95. doi: 10.1007/s10549-016-3889-6. Epub 2016 Jul 8.

13.

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance.

Paoletti C, Larios JM, Muñiz MC, Aung K, Cannell EM, Darga EP, Kidwell KM, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese DA, Schott AF, Henry NL, Rae JM, Hayes DF.

Mol Oncol. 2016 Aug;10(7):1078-85. doi: 10.1016/j.molonc.2016.04.006. Epub 2016 Apr 29.

14.

Adjuvant Trastuzumab Benefit in Patients Diagnosed With Triple-Positive Breast Cancer.

Schott AF.

JAMA Oncol. 2016 Aug 1;2(8):1047-8. doi: 10.1001/jamaoncol.2016.0446. No abstract available.

PMID:
27099974
15.

Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.

Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, Van Poznak CH, Wicha MS, Hayes DF, Henry NL.

Breast Cancer Res Treat. 2016 Feb;155(3):589-95. doi: 10.1007/s10549-016-3705-3. Epub 2016 Feb 13.

16.

The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers.

Schott AF, Welch JJ, Verschraegen CF, Kurzrock R.

Semin Oncol. 2015 Oct;42(5):731-9. doi: 10.1053/j.seminoncol.2015.07.010. Epub 2015 Jul 10. Review.

17.

Personalized Medicine: Genomics Trials in Oncology.

Hayes DF, Schott AF.

Trans Am Clin Climatol Assoc. 2015;126:133-43. Review.

18.

Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator?

Hayes DF, Schott AF.

J Natl Cancer Inst Monogr. 2015 May;2015(51):36-9. doi: 10.1093/jncimonographs/lgv004.

PMID:
26063884
19.

Genome Medicine in Cancer: What's in a Name?

Schott AF, Perou CM, Hayes DF.

Cancer Res. 2015 May 15;75(10):1930-5. doi: 10.1158/0008-5472.CAN-15-0174. Epub 2015 Apr 28. Review.

20.

Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy.

Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD.

PLoS One. 2015 Mar 27;10(3):e0122151. doi: 10.1371/journal.pone.0122151. eCollection 2015.

21.

Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.

Paoletti C, Muñiz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, Brown ME, Aung K, Miller MC, Blossom DL, Schott AF, Henry NL, Rae JM, Connelly MC, Chianese DA, Hayes DF.

Clin Cancer Res. 2015 Jun 1;21(11):2487-98. doi: 10.1158/1078-0432.CCR-14-1913. Epub 2014 Nov 7.

22.

Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility.

Henry NL, Schott AF, Hayes DF.

J Clin Oncol. 2014 Oct 10;32(29):3207-9. doi: 10.1200/JCO.2014.57.6132. Epub 2014 Sep 8. No abstract available.

PMID:
25199749
23.

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF.

J Clin Oncol. 2014 Nov 1;32(31):3483-9. doi: 10.1200/JCO.2014.56.2561. Epub 2014 Jun 2.

24.

Image registration for quantitative parametric response mapping of cancer treatment response.

Boes JL, Hoff BA, Hylton N, Pickles MD, Turnbull LW, Schott AF, Rehemtulla A, Chamberlain R, Lemasson B, Chenevert TL, Galbán CJ, Meyer CR, Ross BD.

Transl Oncol. 2014 Feb 1;7(1):101-10. eCollection 2014 Feb.

25.

Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer.

Henry NL, Conlon A, Kidwell KM, Griffith K, Smerage JB, Schott AF, Hayes DF, Williams DA, Clauw DJ, Harte SE.

J Pain. 2014 May;15(5):468-75. doi: 10.1016/j.jpain.2014.01.487. Epub 2014 Jan 22.

26.

Prediction of postchemotherapy ovarian function using markers of ovarian reserve.

Henry NL, Xia R, Schott AF, McConnell D, Banerjee M, Hayes DF.

Oncologist. 2014 Jan;19(1):68-74. doi: 10.1634/theoncologist.2013-0145. Epub 2013 Dec 6.

27.

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM.

Nat Genet. 2013 Dec;45(12):1446-51. doi: 10.1038/ng.2823. Epub 2013 Nov 3.

28.

Predictors of recovery of ovarian function during aromatase inhibitor therapy.

Henry NL, Xia R, Banerjee M, Gersch C, McConnell D, Giacherio D, Schott AF, Pearlman M, Stearns V, Partridge AH, Hayes DF.

Ann Oncol. 2013 Aug;24(8):2011-6. doi: 10.1093/annonc/mdt149. Epub 2013 Apr 23.

29.

Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.

Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC.

Clin Cancer Res. 2013 Mar 15;19(6):1512-24. doi: 10.1158/1078-0432.CCR-11-3326. Epub 2013 Jan 22.

30.

Defining the benefits of neoadjuvant chemotherapy for breast cancer.

Schott AF, Hayes DF.

J Clin Oncol. 2012 May 20;30(15):1747-9. doi: 10.1200/JCO.2011.41.3161. Epub 2012 Apr 16. No abstract available.

PMID:
22508810
31.

Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.

Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL 3rd, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN.

Oncologist. 2012;17(2):179-87. doi: 10.1634/theoncologist.2011-0235. Epub 2012 Jan 20.

32.

Evaluation of an automatic registration-based algorithm for direct measurement of volume change in tumors.

Sarkar S, Johnson TD, Ma B, Chenevert TL, Bland PH, Park H, Schott AF, Ross BD, Meyer CR.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):1038-46. doi: 10.1016/j.ijrobp.2011.07.040. Epub 2011 Dec 14.

33.

Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms.

Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, Griggs JJ, Hayes DF.

Cancer. 2011 Dec 15;117(24):5469-75. doi: 10.1002/cncr.26230. Epub 2011 Jun 20.

34.

Spatial registration of temporally separated whole breast 3D ultrasound images.

Narayanasamy G, LeCarpentier GL, Roubidoux M, Fowlkes JB, Schott AF, Carson PL.

Med Phys. 2009 Sep;36(9):4288-300.

35.

Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.

Svahn TH, Niland JC, Carlson RW, Hughes ME, Ottesen RA, Theriault RL, Edge SB, Schott AF, Bookman MA, Weeks JC.

J Natl Compr Canc Netw. 2009 Feb;7(2):115-21.

PMID:
19200415
36.

Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence.

Kilbride KE, Lee MC, Nees AV, Cimmino VM, Diehl KM, Sabel MS, Hayes DF, Schott AF, Kleer CG, Chang AE, Newman LA.

Ann Surg Oncol. 2008 Nov;15(11):3252-8. doi: 10.1245/s10434-008-0136-3. Epub 2008 Sep 11.

PMID:
18784961
37.

Monitoring serial changes in circulating human breast cancer cells in murine xenograft models.

Eliane JP, Repollet M, Luker KE, Brown M, Rae JM, Dontu G, Schott AF, Wicha M, Doyle GV, Hayes DF, Luker GD.

Cancer Res. 2008 Jul 15;68(14):5529-32. doi: 10.1158/0008-5472.CAN-08-0630.

38.

Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.

Layman RM, Thomas DG, Griffith KA, Smerage JB, Helvie MA, Roubidoux MA, Diehl KM, Newman LA, Sabel MS, Hayman JA, Pierce LJ, Hayes DF, Schott AF.

Clin Cancer Res. 2007 Jul 15;13(14):4092-7.

39.

Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy.

Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, Khan AP, Helvie M, Meyer CR, Chenevert TL, Rehemtulla A, Ross BD.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):443-50.

40.

Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.

Schott AF, Rae JM, Griffith KA, Hayes DF, Sterns V, Baker LH.

Cancer Chemother Pharmacol. 2006 Jul;58(1):129-35. Epub 2005 Nov 8.

41.

Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.

Schott AF, Roubidoux MA, Helvie MA, Hayes DF, Kleer CG, Newman LA, Pierce LJ, Griffith KA, Murray S, Hunt KA, Paramagul C, Baker LH.

Breast Cancer Res Treat. 2005 Aug;92(3):231-8.

42.

Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy.

Khan A, Sabel MS, Nees A, Diehl KM, Cimmino VM, Kleer CG, Schott AF, Hayes DF, Chang AE, Newman LA.

Ann Surg Oncol. 2005 Sep;12(9):697-704. Epub 2005 Aug 4.

43.

Sonographic evaluation of early-stage breast cancers that undergo neoadjuvant chemotherapy.

Roubidoux MA, LeCarpentier GL, Fowlkes JB, Bartz B, Pai D, Gordon SP, Schott AF, Johnson TD, Carson PL.

J Ultrasound Med. 2005 Jul;24(7):885-95.

44.

Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis.

Pu RT, Schott AF, Sturtz DE, Griffith KA, Kleer CG.

Am J Surg Pathol. 2005 Mar;29(3):354-8.

PMID:
15725804
45.

Fever and neutropenia clinical practice guidelines.

Freifeld AG, Baden LR, Brown AE, Elting LS, Gelfand M, Greene JN, Ito JI, King E, Marcucci G, Montoya JG, Morris A, Noskin G, Rolston K, Schott AF, Segal B; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2004 Sep;2(5):390-432.

PMID:
19780251
46.

A phase I dose escalation trial of gemcitabine with radiotherapy for breast cancer in the treatment of unresectable chest wall recurrences.

Suh WW, Schott AF, Hayman JA, Schipper MJ, Shewach DS, Pierce LJ.

Breast J. 2004 May-Jun;10(3):204-10.

47.

Sentinel node biopsy prior to neoadjuvant chemotherapy.

Sabel MS, Schott AF, Kleer CG, Merajver S, Cimmino VM, Diehl KM, Hayes DF, Chang AE, Pierce LJ.

Am J Surg. 2003 Aug;186(2):102-5.

PMID:
12885598
48.

Bcl-XL protects cancer cells from p53-mediated apoptosis.

Schott AF, Apel IJ, Nuñez G, Clarke MF.

Oncogene. 1995 Oct 5;11(7):1389-94.

PMID:
7478561

Supplemental Content

Loading ...
Support Center